Castor Raises $45M Series B to Modernize the Clinical Trial Process and Maximize the Impact of Research Data on Patient Lives
Castor, a leading provider of clinical trial software, announced today the closing of a $45 million Series B financing round, bringing the company’s total funding to $65 million.
The round, led by Eight Roads Ventures and F-Prime Capital with participation from existing investors Two Sigma Ventures and Inkef Capital, will fuel continued product development with a particular focus on scaling direct-to-patient trials globally.
“Castor was created with the mission to help researchers globally conduct more effective clinical trials while improving the patient experience,” said Derk Arts, M.D., CEO & Founder of Castor. “Prioritizing the patient and site user experience is particularly important today, when COVID-19 has fundamentally changed the nature of clinical trials.”
Most clinical trials today require a long set-up time and are conducted at brick-and-mortar research sites which make trial participation inconvenient for patients and leave researchers in the dark about patient data in-between site visits. As a result, 38.7% of terminated trials being halted due to slow enrollment¹, and the cost to develop a drug has more than doubled in the last decade to $2.7 billion across a 12-year timeline².
Castor offers a modern, self-service clinical research platform, which enables every researcher worldwide to design studies and integrate data from any source in real-time. Patients can enroll themselves in trials, consent and share their data online or via a mobile app, allowing the industry to seamlessly shift to decentralized clinical trials (DCT). These capabilities have been critical during the COVID-19 pandemic as Castor’s customers were able to quickly change their study designs and incorporate increased collection of remote patient data.
Since 2014, Castor has supported over 7,500 studies in more than 90 countries. Over the last 12 months, the company more than doubled in size and it has worked with customers such as the World Health Organization, which used Castor for its Solidarity Trial, and landed contracts with over 20 top-tier digital therapeutics companies and signed its first top 5 pharmaceutical company.
“COVID-19 forced the industry to change and required agility and customer centricity that Castor was uniquely positioned to deliver,” said Michael Treskow, Partner at Eight Roads Ventures.
“We believe that Castor’s visionary approach will significantly improve the quality of clinical research and we are excited to support Derk and the team as they continue to transform the industry on a global scale,” said Alex Pasteur, Partner at F-Prime Capital.
1. Williams RJ, et al. Terminated Trials in the ClinicalTrials.gov Results Database: evaluation of availability of primary outcome data and reasons for termination. PLoS One. 2015;10(5):e0127242.
2. J. DiMasi, et al. Innovation in the pharmaceutical industry: New estimates of R&D costs, Journal of Health Economics, Volume 47, 2016, Pages 20-33
Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug and play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, consent and real-world data capture. Castor is bringing human-centered design to the clinical trial process, from recruitment to analysis, and improving the quality, security and reusability of data for researchers worldwide. For more information, visit www.castoredc.com.
About Eight Roads Ventures
Eight Roads Ventures is a global venture capital firm managing $7bn of assets across offices in the UK, China, India, Japan, and the US. Our 50-year history of investing includes partnerships with over 300 companies such as Alibaba, Appsflyer, BlackDuck, Cazoo, Chewy, Devoted Health, Flywire, Icertis, iPipeline, Kensho, Letgo, Made.com, Neo4j, Nuance, Paidy, Ping Identity, Pony.ai, Toast, Wallapop, WuXi PharmaTech, and Xoom.
About F-Prime Capital
F-Prime Capital is a global venture capital firm investing in healthcare and technology. For the past 50 years, our independent venture capital group has had the privilege of backing great entrepreneurs building groundbreaking companies.
With over $2 billion dollars under management and a global portfolio of more than 200 companies, we champion those dedicated to creating positive change in the world. In healthcare, we focus on therapeutics, medtech and health IT & services in a stage-agnostic fashion. Our healthcare fund has created or co-created 23 companies including Denali, Beam, Innovent, Orchard and Sana and has helped build many others including Blueprint Medicines, Iora Health, PatientPing, Devoted and Ultragenyx. F-Prime portfolio companies have seen more than 28 products and drugs approved by regulatory agencies worldwide. Our team of investors, engineers, doctors and scientists is committed to bringing the insight, domain expertise and relationships required to help our companies make a transformational impact.
F-Prime is headquartered in Cambridge, MA, with offices in London, UK and San Francisco, CA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Discover the History of Pisco, the Spirit Drink That Was Born in Peru 400 Years Ago28.7.2021 13:00:00 CEST | Press release
Every lover of spirits should know about pisco. Therefore, it is not surprising that this distillate has achieved international notoriety and been included as a de rigueur item of the ultimate bucket list in “Captain America: Winter Soldier” in 2014. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210728005437/en/ (Photo: Business Wire) What many don't know is its origin and the fascinating journey it would make 200 years later: in 1553, the vines of the Canary Islands arrived in Peru with the strains that gave rise to pisco (Quechua word for “bird,” which is also the name of a Peruvian city founded in 1640 by viceroy Pedro Toledo y Leyva) and in 1779, navigator Francisco de la Bodega y Quadra took this drink from Pisco (Peru) to San Francisco for the first time, when both cities were still part of the Spanish empire. Thus, in 1850 the Pisco Punch was created, the flagship cocktail for the entire West Coast of the United Stat
FRISS Raises $65 Million Series B Funding Led by Accel-KKR28.7.2021 13:00:00 CEST | Press release
FRISS, the most widely adopted provider of AI-powered end-to-end fraud prevention and detection solutions for P&C insurers worldwide, today announced it closed a $65 million Series B funding round led by Accel-KKR, advised by FT Partners and endorsed by existing investor, Aquiline. The funding will fuel the company’s rapid growth with additional product innovations, deep market penetration and lines of business expansions. FRISS serves insurers in over forty countries today, and is well on track to deliver over $2 billion in fraud savings to insurers in 2021 alone. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210728005113/en/ FRISS Raises $65 Million Series B Funding Led By Accel-KKR (Graphic: Business Wire) Insurance fraud is a large and growing problem faced by insurance companies, with estimates of fraud in as much as 10-17% of total claims paid annually – a staggering $80 billion annual loss in the US insurance market
Total Telecom: Mass Production of 14nm Chips in China Will be Achieved Next Year28.7.2021 12:00:00 CEST | Press release
Total Telecom reports that after gaining competency in manufacturing 28nm chips, China is moving towards realizing mass production of 14nm chips in the coming year. According to Dr Yungang Bao, Assistant Director at the Institute of Computing Technology, the domestic 14nm chip has overcome many technical challenges and all aspects of the domestic 14nm chip will be dramatically improved, leading to mass production. 28nm chips are cost-effective and known to consume less power while delivering high performance. Total Telecom reports that the development of the 28nm technology will help the Chinese chip industry address domestic demand, as it is already a mature technology and is used in new areas such as 5G, new energy vehicles, UHV, big data centers, artificial intelligence (AI), and the industrial Internet. This is significant considering that China is the world's biggest consumer of semiconductors. 14nm chips are widely accepted as the most valuable process technology, as they have va
Gupshup Raises Additional $240 Million to Fast-Track Global Conversational Messaging Vision28.7.2021 12:00:00 CEST | Press release
Gupshup, the leader in conversational messaging, today announced it has raised an additional $240 million in follow-on funding from an industry-leading group of investors including Fidelity Management and Research Company LLC, Tiger Global, Think Investments, Malabar Investments, Harbor Spring Capital, certain accounts managed by Neuberger Berman Investment Advisers LLC, White Oak, Neeraj Arora and others.This funding round follows the $100 million raise from Tiger Global in April, at a $1.4 billion valuation. Gupshup will use this investment to continue executing its vision and for secondary purchase of shares from current and former employees as well as prior investors. Gupshup continues to invest in product innovation for digital commerce enablement as well as expanding go-to-market initiatives in mobile-first economies around the world. Gupshup is also exploring M&A opportunities to expand its business opportunities. The company earlier announced an expansion in its executive team
Workiva Extends Value of Cloud Platform with Launch of New SaaS Marketplace28.7.2021 10:15:00 CEST | Press release
Workiva Inc. (NYSE:WK), today launched The Workiva Marketplace, filled with more than 140 Workiva-built and partner templates, services and 60 no-code connectors that streamline existing processes and solve new business problems all within the Workiva cloud platform’s connected and secure ecosystem. The Workiva Marketplace’s offerings include: process checklists, carefully organized and linked reports, style guides, perfectly formatted presentations, and more. Accounting, audit, financial planning & analysis, financial services, and legal teams can easily add templates or connectors directly into an existing Workiva workspace and optimize workflow with process automation, practical examples, and industry best practices. Comments on the News: “There is an enormous opportunity for organizations to scale their business operations efficiently and cost effectively by leveraging Workiva’s connected ecosystem,” said Julie Iskow, COO of Workiva. “The Workiva Marketplace allows users to find to
Nordic Enterprises Moving Forward with SAP S/4HANA Initiatives to Meet Challenges of COVID-1928.7.2021 10:00:00 CEST | Press release
Enterprises in the Nordics are addressing the challenges of the COVID-19 pandemic by adopting cloud services and reworking their IT strategies and technology roadmaps, according to a new report published today by Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm. The 2021 ISG Provider Lens™ SAP HANA Ecosystem Services report for the Nordics finds large-scale, long-term system transformations in the region, including SAP S/4HANA projects, have continued despite slowing down briefly early in the pandemic. To continue operating under the new business conditions, many companies are moving their workloads to the cloud. “With help from service providers, companies in the Nordics continue to innovate with SAP applications,” said Jan Erik Aase, partner and global leader, ISG Provider Lens Research. “Providers’ skilled management of offshore services have kept SAP projects on plan, with only minor delays due to the pandemic.” Many enterprises
Värde Partners Agrees €96 Million Sale of Hotel Barcelona Apolo to Meliá28.7.2021 10:00:00 CEST | Press release
Värde Partners, a leading global alternative investment firm, announced it has agreed to the sale of Hotel Barcelona Apolo to Meliá Hotels International, the current hotel operator, for €96 million. The transaction followed an open bidding process that attracted interest from more than 20 institutional investors. The sale was agreed through Dospuntos Asset Management, a Värde-controlled real estate company in Spain, formed in December 2017 from the residential developer Vía Célere. Since the acquisition of the hotel in 2015 Värde has executed a series of value creation initiatives, including refinancing the business and delivering a comprehensive investment program, to establish Hotel Barcelona Apolo as a leading destination for international tourists and corporate events. “The timing of the sale reflects our conviction in the underlying quality of the hotel, and the enduring appeal of Barcelona as a destination for international capital. There was strong demand for the asset demonstra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom